View Item 

Show simple item record

Is a level III dissection necessary for a positive sentinel lymph node in melanoma?
dc.contributor.authorNamm, Jukes P.en_US
dc.contributor.authorChang, Alfred E.en_US
dc.contributor.authorCimmino, Vincent M.en_US
dc.contributor.authorRees, Riley S.en_US
dc.contributor.authorJohnson, Timothy M.en_US
dc.contributor.authorSabel, Michael S.en_US
dc.date.accessioned2012-03-16T16:01:26Z
dc.date.available2013-05-01T17:24:43Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationNamm, Jukes P.; Chang, Alfred E.; Cimmino, Vincent M.; Rees, Riley S.; Johnson, Timothy M.; Sabel, Michael S. (2012). "Is a level III dissection necessary for a positive sentinel lymph node in melanoma?." Journal of Surgical Oncology 105(3): 225-228. <http://hdl.handle.net/2027.42/90389>en_US
dc.identifier.issn0022-4790en_US
dc.identifier.issn1096-9098en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90389
dc.description.abstractBackground For melanoma patients with a positive axillary SLN, the extent of ALND remains controversial, with debate over whether a level III dissection is needed. Methods We queried our IRB approved prospective database for patients with a positive axillary SLN who had a level I/II dissection only, and compared recurrence and complication rates to the existing literature. Results Between 1998 and 2008, 270 patients had 285 level I/II ALNDs for a positive SLN. Median number of SLN removed was 2, while the median number of involved SLN was 1 (range 1–4). An average of 18.7 nodes/ALND were removed, with 13% having positive non‐SLN. Post‐operative complications occurred in 31 patients (11%), primarily cellulitis (8%). After a mean follow‐up of 44 months, 14 patients had a regional recurrence in the axillary basin (5%). Conclusions The complication rate and regional recurrence rate for patients undergoing a level I/II ALND for a positive SLN are either lower than or on par with reported series of ALND for level I, II, and III dissections, suggesting that in this setting, the level III dissection may be of minimal benefit. J. Surg. Oncol. 2012; 105:225–228. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherMelanomaen_US
dc.subject.otherAxillary Lymph Node Dissectionen_US
dc.subject.otherSentinel Lymph Node Biopsyen_US
dc.titleIs a level III dissection necessary for a positive sentinel lymph node in melanoma?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Dermatology, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationother3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109. Fax: +1‐734‐647‐9647.en_US
dc.identifier.pmid21882199en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90389/1/22076_ftp.pdf
dc.identifier.doi10.1002/jso.22076en_US
dc.identifier.sourceJournal of Surgical Oncologyen_US
dc.identifier.citedreferenceGuggenheim MM, Hug U, Jung FJ, et al.: Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 2008; 247: 687 – 693.en_US
dc.identifier.citedreferenceMorton DL, Thompson JF, Cochran AJ, et al.: Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307 – 1317.en_US
dc.identifier.citedreferenceGarbe C, Hauschild A, Volkenandt M, et al.: Evidence‐based and interdisciplinary consensus‐based German guidelines: Systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008; 18: 152 – 160.en_US
dc.identifier.citedreferenceEssner R: Surgical treatment of malignant melanoma. Surg Clin N Am 2003; 83: 109 – 156.en_US
dc.identifier.citedreferenceNCCN: Clinical Practical Guidelines in Oncology‐ Melanoma. 2011. (Accessed 12/21, 2010, at http://www.nccn.org/profesionals/physician_gls/PDF/melanoma.pdf.).en_US
dc.identifier.citedreferenceKarakousis CP: Therapeutic node dissections in malignant melanoma. Ann Surg Oncol 1998; 5: 473 – 482.en_US
dc.identifier.citedreferenceMeyer T, Merkel S, Gohl J, et al.: Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28: 424 – 430.en_US
dc.identifier.citedreferenceSerpell JW, Carne PW, Bailey M: Radical lymph node dissection for melanoma. ANZ J Surg 2003; 73: 294 – 299.en_US
dc.identifier.citedreferenceSakorafas GH, Peros G, Cataliotti L, et al.: Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 2006; 15: 153 – 165.en_US
dc.identifier.citedreferenceLarson D, Weinstein M, Goldberg I, et al.: Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 1575 – 1582.en_US
dc.identifier.citedreferenceSilberman H: Axillary lymphadenectomy for breast cancer: Impact on survival. In: Silberman H, Silberman A, editors. Surgical oncology: Multidisciplinary approach to difficult problems. London: Arnold; 2002. pp. 369 – 385.en_US
dc.identifier.citedreferenceKiel K, Rademaker AW: Early‐stage breast cancer: Arm edema after wide excision and breast irradiation. Radiology 1996; 1998: 279 – 283.en_US
dc.identifier.citedreferenceSuneson BL: Clinical incidence of lymphedema in breast cancer patients in Jonkoping County, Sweden. Eur J Cancer Care 1996; 5: 1 – 12.en_US
dc.identifier.citedreferenceSondak VK, Taylor JM, Sabel MS, et al.: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11: 247 – 258.en_US
dc.identifier.citedreferenceFrankel TL, Griffith KA, Lowe L, et al.: Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 2008; 15: 2403 – 2411.en_US
dc.identifier.citedreferenceWrightson WR, Wong SL, Edwards MJ, et al.: Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Onc 2003; 10: 676 – 780.en_US
dc.identifier.citedreferenceKretschmer L, Thoms KM, Peeters S, et al.: Postoperative morbidity of lymph node excision for cutaneous melanoma‐sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 2008; 18: 16 – 21.en_US
dc.identifier.citedreferencede Vries M, Vonkeman WG, van Ginkel RJ, et al.: Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol 2005; 31: 778 – 783.en_US
dc.identifier.citedreferenceGershenwald JE, Berman RS, Porter G, et al.: Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2000; 7: 226 – 231.en_US
dc.identifier.citedreferenceClary BM, Brady MS, Lewis JJ, et al.: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single‐institution experience with an emphasis on recurrence. Ann Surg 2001; 233: 250 – 258.en_US
dc.identifier.citedreferenceLeiter U, Buettner PG, Bohnenberger K, et al.: Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol 17: 129 – 137.en_US
dc.identifier.citedreferenceVeenstra HJ, van der Ploeg IM, Wouters MW, et al.: Reevaluation of the locoregional recurrence rate in melanoma patients with a positive sentinel node compared to patients with palpable nodal involvement. Ann Surg Oncol 17: 521 – 526.en_US
dc.identifier.citedreferenceBalch CM, Durant JR, Bartolucci AA: The impact of surgical quality control in multi‐institutional group trials involving adjuvant cancer treatments. Ann Surg 1983; 198: 164 – 167.en_US
dc.identifier.citedreferenceMorton DL, Cochran AJ, Thompson JF, et al.: Sentinel node biopsy for early‐stage melanoma: Accuracy and morbidity in MSLT‐I, an international multicenter trial. Ann Surg 2005; 242: 302 – 313.en_US
dc.identifier.citedreferenceSpillane AJ, Cheung BL, Stretch JR, et al.: Proposed quality standards for regional lymph node dissections in patients with melanoma. Ann Surg 2009; 249: 473 – 480.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
22076_ftp.pdf
Size:
69.05KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.